The spring ACS national meeting is just around the corner, and with it, as always, comes the unveiling of a few drug candidates’ structures. This symposium is always held in a big ballroom, and it’s always packed.
I’ll be liveblogging the “First Disclosures of Clinical Candidates” symposium, which is this Sunday, March 21, from 2PM to 5PM Pacific. You can follow my updates at C&EN’s new pharma blog, The Haystack. (Link will be live Sunday).
My updates will also appear on Twitter. You don’t have to have a twitter account to see these updates. But if you do use twitter just follow me @carmendrahl
To read the abstracts, visit the ACS meeting technical program, click on the ‘divisions’ tab, select the MEDI division, and then select “First Time Disclosures”.
Some food for thought before Sunday: 4 of the 6 talks appear to be about targeting G-protein-coupled receptors (GPCRs). Last year the stat was two out of six. It always makes for a good talk when GPCRs and other membrane-bound proteins are involved. Since it’s unlikely that there will be detailed structural information on the target (like an X-ray crystal structure) for teams to go on when optimizing their drug candidate, teams have to be resourceful.